These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8710920)

  • 21. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
    Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
    Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
    Krop IE; Beeram M; Modi S; Jones SF; Holden SN; Yu W; Girish S; Tibbitts J; Yi JH; Sliwkowski MX; Jacobson F; Lutzker SG; Burris HA
    J Clin Oncol; 2010 Jun; 28(16):2698-704. PubMed ID: 20421541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glutathione-Sensitive Hyaluronic Acid-SS-Mertansine Prodrug with a High Drug Content: Facile Synthesis and Targeted Breast Tumor Therapy.
    Zhong P; Zhang J; Deng C; Cheng R; Meng F; Zhong Z
    Biomacromolecules; 2016 Nov; 17(11):3602-3608. PubMed ID: 27723970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models.
    Morimura O; Minami T; Kijima T; Koyama S; Otsuka T; Kinehara Y; Osa A; Higashiguchi M; Miyake K; Nagatomo I; Hirata H; Iwahori K; Takimoto T; Takeda Y; Kida H; Kumanogoh A
    Biochem Biophys Res Commun; 2017 Jul; 488(4):596-602. PubMed ID: 28526406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
    Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
    J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)].
    Gonçalves A; Trédan O; Villanueva C; Dumontet C
    Bull Cancer; 2012 Dec; 99(12):1183-91. PubMed ID: 23247898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry.
    Wang L; Amphlett G; Blättler WA; Lambert JM; Zhang W
    Protein Sci; 2005 Sep; 14(9):2436-46. PubMed ID: 16081651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Revival of a potent therapeutic maytansinoid agent using a strategy that combines covalent drug conjugation with sequential nanoparticle assembly.
    Xie K; Song S; Zhou L; Wan J; Qiao Y; Wang M; Xie H; Zhou L; Zheng S; Wang H
    Int J Pharm; 2019 Feb; 556():159-171. PubMed ID: 30553007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.
    Junttila TT; Li G; Parsons K; Phillips GL; Sliwkowski MX
    Breast Cancer Res Treat; 2011 Jul; 128(2):347-56. PubMed ID: 20730488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
    Calvete JA; Newell DR; Wright AF; Rose MS
    Cancer Res; 1994 Sep; 54(17):4684-90. PubMed ID: 8062265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.
    Erickson HK; Park PU; Widdison WC; Kovtun YV; Garrett LM; Hoffman K; Lutz RJ; Goldmacher VS; Blättler WA
    Cancer Res; 2006 Apr; 66(8):4426-33. PubMed ID: 16618769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes.
    Starling JJ; Maciak RS; Law KL; Hinson NA; Briggs SL; Laguzza BC; Johnson DA
    Cancer Res; 1991 Jun; 51(11):2965-72. PubMed ID: 2032233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
    Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
    Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.
    Sun X; Widdison W; Mayo M; Wilhelm S; Leece B; Chari R; Singh R; Erickson H
    Bioconjug Chem; 2011 Apr; 22(4):728-35. PubMed ID: 21391620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
    Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
    Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
    Trail PA; Willner D; Lasch SJ; Henderson AJ; Greenfield RS; King D; Zoeckler ME; Braslawsky GR
    Cancer Res; 1992 Oct; 52(20):5693-700. PubMed ID: 1382845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
    Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Technology evaluation: cantuzumab mertansine, ImmunoGen.
    Smith SV
    Curr Opin Mol Ther; 2004 Dec; 6(6):666-74. PubMed ID: 15663331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity.
    Ríos-Luci C; García-Alonso S; Díaz-Rodríguez E; Nadal-Serrano M; Arribas J; Ocaña A; Pandiella A
    Cancer Res; 2017 Sep; 77(17):4639-4651. PubMed ID: 28687619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.